1. Introduction {#sec0001}
===============

Motor neuron diseases (MND) encompass a range of clinically heterogeneous conditions which typically affect young adults, are relentlessly progressive and have no effective disease-modifying therapies ([@bib0001]). Some of the barriers to the development of effective pharmacological interventions include the considerable clinical heterogeneity of the condition, lack of validated biomarkers and late recruitment into pharmacological trials ([@bib0002]; [@bib0003]; [@bib0004]). The majority of imaging studies in MND focus on cortical grey matter atrophy ([@bib0005]; [@bib0006]), corticospinal tract degeneration ([@bib0007]), corpus callosum pathology ([@bib0008]; [@bib0009]) and spinal cord degeneration ([@bib0010]; [@bib0011]; [@bib0012]). With the recognition of extra-motor deficits in MND ([@bib0091]; [@bib0013]; [@bib0014]; [@bib0015]; [@bib0016]) the frontotemporal ([@bib0017]; [@bib0090]), basal ganglia ([@bib0018]; [@bib0019]) and cerebellar ([@bib0020]) profiles of MNDs have also been gradually characterised ([@bib0021]), but there remains a striking lack of dedicated brainstem studies. Brainstem pathology is a hallmark feature of the disease and has been associated with the condition since its earliest descriptions ([@bib0022]). In one of the first pathologically supported reports, Lockhart Clarke eloquently describes progressive bulbar involvement in a patient with ALS: "September 1865; Her voice changed; she did not pronounce words as usual...Her deglutition now became difficult... The tongue is protruded badly; about a quarter of an inch beyond the lower teeth. It is atrophied on each side, and in folds, reminding one of cerebral convolutions. Her talking is nearly unintelligible; to me it is generally quite unintelligible, but the nurse can usually manage to make out what the patient says." This moving description from over 150 years ago illustrates the bulbar symptoms in ALS which continue to affect patients today ([@bib0023]). Following his clinical description, Clarke comments on post mortem brainstem changes; "The medulla oblongata was below the average size. It was not, however, softer than usual, nor was it anywhere damaged by disintegration of tissue; but many of its nerve-cells, particularly about the floor of the fourth ventricle and calamus scriptorius, were in different stages of degeneration." Despite historical descriptions of brainstem atrophy, it remains surprisingly understudied in vivo, in spite of considerable advances in ALS neuroimaging ([@bib0024]). Moreover, brainstem pathology is regarded as 'stage 1' of a recently proposed four-stage pathological staging system based on pathological TDP-43 burden patterns ([@bib0025]). Furthermore, brainstem pathology is not unique to ALS, it is a unifying feature of most motor neuron diseases (ALS, PLS, SBMA) affecting the descending pyramidal tracts, brainstem nuclei or both, depending on the phenotype ([@bib0025]; [@bib0026]; [@bib0027]; [@bib0028]; [@bib0029]). So, while brainstem degeneration is a pathognomonic feature of most MNDs, it is seldom evaluated specifically in dedicated imaging studies. This is a missed opportunity at a time when wet and dry biomarkers are urgently sought to inform clinical trial outcomes ([@bib0030]; [@bib0031]). Accordingly, our main objective is the systematic characterisation of brainstem involvement in ALS and PLS, using both healthy- and disease controls in a prospective longitudinal study design. Based on the extensive post mortem literature of the disease ([@bib0025]; [@bib0029]), we hypothesise that brainstem pathology can not only be detected in vivo, but it exhibits progressive changes over time.

2. Methods {#sec0002}
==========

2.1. Ethics statement {#sec0003}
---------------------

The study protocol, recruitment, and data management procedures were approved by our institutional ethics committee (Beaumont Hospital, Dublin, Ireland), in accordance with the 1964 Helsinki declaration and its later amendments. All participants provided informed consent and data was handled in accordance with the relevant EU regulations (GDPR).

2.2. Participants {#sec0004}
-----------------

A total of 100 ALS patients, 33 patients with PLS, 30 patients with FTD, and 100 healthy controls were included. Exclusion criteria included prior traumatic brain injury, prior cerebrovascular events, space-occupying intracranial findings, and inability to undergo MRI scanning due to implanted metallic devices (baclofen pumps, pacemakers), claustrophobia, or orthopnoea. Participating ALS patients had 'probable' or 'definite' ALS according to the El Escorial criteria ([@bib0032]), PLS patients were diagnosed based on the Gordon criteria ([@bib0033]) and FTD patients diagnosed in accordance with the Rascovsky criteria ([@bib0034]). ALS patients were scanned twice with a follow-up interval of 4 months. Healthy controls had no known neurological or psychiatric conditions, previous head injuries or established vascular risk factors and no family history of neurodegenerative conditions.

2.3. Neuroimaging methods {#sec0005}
-------------------------

T~1~-weighted images were acquired on a 3 Tesla Philips Achieva system using an 8-channel receive-only head coil using a 3D Inversion Recovery prepared Spoiled Gradient Recalled echo (IR-SPGR) sequence with the following settings; spatial resolution: 1 mm^3^, field-of-view (FOV): 256 × 256 × 160 mm, TR/TE = 8.5/3.9 ms, TI = =1060 ms, flip angle = 8°, SENSE factor = 1.5, acquisition time: 7 min 30 s. A multimodal approach was undertaken to comprehensively characterise brainstem degeneration in MND. First, total intracranial volumes (TIV) were estimated and a model-based approach utilised to estimate the volume of the entire brainstem. Subsequently, a Bayesian segmentation algorithm was used to estimate the volumes of the medulla oblongata, pons, and midbrain. Brainstem atrophy patterns in ALS were evaluated with reference to healthy controls, disease controls and PLS patients using vertex analyses. Finally, region of interest morphometry analyses were carried out to evaluate focal brain stem alterations in the study groups.

2.4. TIV and total brainstem volumes {#sec0006}
------------------------------------

Total intracranial volume (TIV) was calculated for each study participant to be used as a covariate for subsequent volumetric comparisons. The FMRIB Software Library (FSL) was used for TIV estimations. Each subject\'s skull-stripped brain was linearly aligned to the standard MNI152 brain image, the inverse of the determinant of the affine registration matrix was calculated and multiplied by the size of the template. FSL-FLIRT was used for registration to template ([@bib0035]), and tissue type segmentation was performed using FSL-FAST ([@bib0036]). For the estimation of total brain stem volume the model-based approach of FSL-FIRST was implemented. As described previously ([@bib0037]), FSL-FIRST ([@bib0038]) uses a two-stage affine registration approach to register raw T1 data sets to the Montreal Neurological Institute 152 (MNI152) standard space first and then a model-based method is implemented for the segmentation of subcortical structures.

2.5. Brainstem segmentation {#sec0007}
---------------------------

A Bayesian segmentation algorithm was used for the segmentation of the brainstem into the medulla oblongata, pons and midbrain. The protocol relies on a probabilistic atlas of the brainstem and its neighbouring anatomical structures generated based on 49 scans ([@bib0039]). The FreeSurfer image analysis suite ([@bib0040]) was used for the pre-processing of T1-wieghted data which included the removal of non-brain tissue, segmentation of the subcortical white matter and deep grey matter structures, intensity normalization, tessellation of the grey matter-white matter boundary, and automated topology correction. Subsequent to pre-processing and brainstem segmentation, raw volumetric values were retrieved for each study participant at each timepoint for statistical interpretation with the appropriate covariates.

2.6. Vertex analyses {#sec0008}
--------------------

In order to characterise anatomical patterns of degenerative change in the brainstem beyond overall volume reductions, shape analyses were performed between the relevant study groups. FMRIB\'s subcortical segmentation and registration tool FIRST ([@bib0038]) was used for vertex analyses to generate quantitative, surface-projected information about focal brainstem involvement. Vertex locations of individual participants were projected on the surface of an average template shape as scalar values, positive value being outside the surface and negative values inside. Permutation based non-parametric statistics were used for group comparisons, design matrices included age, gender and education ([@bib0041]), probability maps were corrected for multiple comparisons, and a statistical threshold of *p* \< .05 FWE was considered significant.

2.7. Region of interest morphometry {#sec0009}
-----------------------------------

In order to detect focal density alterations within the brain stem, region-of-interest morphometry was performed to complement the vertex analyses. The FMRIB Software Library (FSL) was used for brain extraction and tissue-type segmentation, following which grey-matter partial volume images were aligned to the MNI152 standard space using affine registration. Subsequently, a study specific template was created, to which the grey matter images from each subject were non-linearly coregistered. A voxelwise generalized linear model and permutation-based non-parametric testing was used to highlight density alterations in a merged brainstem mask accounting for age, gender and education ([@bib0041]; [@bib0042]). The labels of the Harvard-Oxford probabilistic structural atlas ([@bib0043]) and the labels of the Talairach probabilistic ([@bib0044]) atlas were used to generate a merged brainstem mask incorporating the medulla oblongata, pons and midbrain.

2.8. Genetics {#sec0010}
-------------

Of the 100 ALS patients, *C9orf72* repeat expansion status was determined in 97 patients ([@bib0045]). DNA samples from patients were tested for the presence of the pathogenic GGGGCC hexanucleotide repeat expansion in *C9orf72* by repeat-primed PCR using the Applied Biosystems (Foster City, CA, USA) 3130xl Genetic Analyser and visualised using GeneMapper version 4.0 as described previously ([@bib0045]; [@bib0046]). Patients carrying more than 30 hexanucleotide repeats were considered positive for the expansion. Whole-genome sequence data were available for 44 ALS patients ([@bib0047]) and targeted DNA sequence data for a further 27 ALS patients ([@bib0048]). Whole exome sequence data were available for 29 of the 33 PLS patients ([@bib0016]). Putative variants were defined as protein altering variants in the exons and splice sites of 33 genes linked to ALS on the ALS online database ([@bib0049]) and 70 genes linked to HSP ([@bib0050]). *C9orf72* hexanucleotide repeat expansion status in the PLS cohort was also determined using repeat-primed polymerase chain reaction (PCR).

2.9. Statistics {#sec0011}
---------------

Analyses of covariance (ANCOVA) were performed to evaluate intergroup differences in brainstem volumes. Assumptions of normality, linearity and homogeneity of variances were verified. Brainstem volumes were included as dependent variables, and study group allocation as the categorical independent variable. TIV, age, education, and gender were included as covariates ([@bib0051]). Summary tables were generated to present the estimated marginal means of brainstem volumes, standard error, between-group ANCOVA significance and *p*-values for Bonferroni-corrected post hoc testing. Estimated marginal means of volumes were plotted with confidence intervals to illustrate the volumetric profile of each study group. To demonstrate the divergent subcortical profiles of ALS, PLS and FTD percentage volume reductions were calculated with reference to the estimated marginal means of healthy controls and plotted on a radar (spider) chart. Differences in longitudinal change between *C9orf72* hexanucleotide carriers and those without the repeat expansions were evaluated with mixed effect models.

3. Results {#sec0012}
==========

Study participants were matched for age, gender, handedness and education. Despite the comparable demographic profile of the study groups, each statistical model of our imaging analyses included age, gender, education and total intracranial volumes as covariates [Table 1](#tbl0001){ref-type="table"}.Table 1The clinical and demographic profile of the study cohorts.Table 1ALS T1 *n *= 100ALS T2 *n *= 100PLS *n *= 33FTD *n *= 30HC *n *= 100*p* valueAge59.83 (11.155)60.21 (11.235)60.48 (10.488)63.97 (14.571)59.65 (11.876)0.484Gender (male)62 (62%)62 (62%)19 (58%)13 (43%)54 (54%)0.332Education (years)13.45 (3.176)13.45 (3.176)12.88 (3.380)12.80 (3.210)12.47 (3.383)0.171Handedness (right)90 (90%)90 (90%)29 (88%)27 (90%)94 (94%).784ALSFRS-r36.62 (7.470)35.40 (7.335)34.36 (5.337)N/aN/a0.23

3.1. Volumetric analyses {#sec0013}
------------------------

The volumetric analyses of brainstem regions revealed considerable multisegmental brainstem atrophy in both ALS and PLS with medullar predominance. ALS patients at their second timepoint exhibited statistically significant volume reductions in both the medulla and pons compared to healthy controls. Total brainstem volume reductions in ALS did not reach statistical significance with reference to controls, suggestive of selective medullar and pontine involvement. In the PLS cohort, brainstem atrophy was detectable in all three regions and medullar atrophy was not only apparent in comparison to healthy-, but also with reference to disease controls. PLS patients also had significantly lower medullar, pontine and mesencephalic volumes compared to ALS patients. Across the two time points ALS patients exhibited progressive volume loss in all three brainstem segments but longitudinal changes did not reach statistical significance. ALS patients showed a trend of medullar atrophy compared to healthy controls at their first time point which has reached significance by their second timepoint. Similarly, while pontine differences were not significant between healthy controls and ALS patients at the first time point, due to progressive pontine volume loss, ALS patients at the their second time point exhibited statistically significant pontine changes ([Table 2](#tbl0002){ref-type="table"} and [Fig. 1](#fig0001){ref-type="fig"}).Table 2Brainstem volumes in healthy controls (HC), patients with frontotemporal dementia (FTD), patients with amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS). Estimated marginal means and standard error are adjusted for age, gender, education and total intracranial volume (TIV) (Covariates appearing in the model are evaluated at the following values: Age = 59.59, Gender = 1.43, Edu = 13.63, TIV = 1435355.28) Pairwise post hoc comparisons are Bonferroni corrected. Significant intergroup differences are flagged with asterisks '\*'. Statistical trends are flagged with superscript 't'. ALS_T1: ALS patients first time point, ALS_T2: ALS patients second time point, FTD: patients with frontotemporal dementia, HC: healthy controls, PLS: patients with primary lateral sclerosis.Table 2StructureStudy groupEstimated marginal means(adjusted for age, gender, education and TIV)Standard errorANCOVA Sig. (p)Post-hoc comparisons\
(Bonferroni-corrected)Medulla\<0.001**ALS T1 vs HC***p* = .061^t^\
**ALS T1 vs PLS***p* = .002\*\
**ALS T2 vs HC***p* \< .001\*\
**ALS T2 vs PLS***p*= = .057 ^t^\
**FTD vs PLS***p* = .001\*\
**HC vs PLS***p* \< .001\*HC4808.6414714.924ALS T14623.07047.012ALS T24530.93747.023FTD4747.98686.610PLS4268.43381.904Pons\<0.001**ALS T1 vs PLS***p* = .003\*\
**ALS T2 vs HC***p* = .017\*\
**ALS T2 vs PLS***p* = .014\*\
**HC vs PLS***p* \< .001\*HC15410.591159.537ALS T114829.294157.394ALS T214699.411157.433FTD14670.462289.969PLS13682.707274.212Midbrain0.004**ALS T1 vs PLS***p* = .073 ^t^\
**HC vs PLS***p* = .02\*HC6173.75749.524ALS T16071.86048.859ALS T26002.52748.871FTD5994.26190.014PLS5807.43185.122Whole Brainstem\< 0.001**ALS T1 vs PLS***p* \< .001\*\
**ALS T2 vs PLS***p* = .002\*\
**FTD vs PLS***p* = .058 ^t^\
**HC vs PLS***p* \< .001\*HC22694.377202.067ALS T122326.919199.353ALS T222038.915199.402FTD21956.655367.272PLS20556.064347.314Fig. 1The volumetric profile of the brainstem in ALS, PLS, disease and healthy controls. *Corners*: Estimate marginal means of the medulla, pons, midbrain are plotted for each study group adjusted for age, gender, education and total intracranial volumes. *Centre*: Percentage volumetric change is plotted with reference to healthy controls. ALS_T1: ALS patients first time point, ALS_T2: ALS patients second time point, FTD: patients with frontotemporal dementia, HC: healthy controls, PLS: patients with primary lateral sclerosis.Fig 1

3.2. Vertex analyses {#sec0014}
--------------------

Focal shape deformations were detected at the second timepoint of ALS patients compared to both disease- and healthy controls following the appropriate statistical corrections. Considerable symmetric medullary pyramid atrophy was detected in comparison to healthy controls. In contrast to disease controls, an asymmetric pattern of anterolateral medullary atrophy was detected which centred on the right pyramid but incorporated the right olivary nuclei. In contrast to PLS, ALS patients exhibited widespread anterior and posterior pontine shape deformations including atrophy of the floor of the fourth ventricle.

3.3. Brainstem morphometry {#sec0015}
--------------------------

Morphometric analyses revealed density reductions in the ALS cohort compared to healthy controls in the mesencephalic crura. The ALS FTD contrast highlighted anterior medullar and central pontine atrophy at the second timepoint of ALS patients compared to disease controls. Compared to PLS patients, the ALS cohort exhibited peri-aqueduct mesencephalic, central pontine and posterior pontine density reductions. No statistically significant morphometric changes were detected between the two timepoints following the appropriate corrections in the ALS cohort.

3.4. Genetics {#sec0016}
-------------

Eleven ALS patients and none of the PLS patients carried the GGGGCC hexanucleotide repeat expansion in *C9orf72*. ALS patients tested negative for other genes previously implicated in ALS. No PLS patients carried ALS or HSP associated mutations. In the ALS cohort, no brainstem differences were identified between hexanucleotide repeat carriers and those without the *C9orf72* mutation at baseline or on follow-up. Moreover, patients with repeat expansions have not shown increased volume loss over time compared to *C9orf72* negative ALS patients.

4. Discussion {#sec0017}
=============

Our study provides evidence of focal and progressive brainstem pathology in ALS and highlights that brainstem alterations can be characterised in vivo using routine MRI sequences. While volumetric analyses provide an overall indication of atrophy, the characterisation of shape deformations and focal density reduction enables the identification of the most vulnerable brainstem regions.

Our data indicate that total brainstem volume reductions are primarily driven by medulla oblongata pathology, but pontine changes also contribute to brainstem atrophy. PLS which is an upper motor neuron disorder ([@bib0028]) exhibits marked medullar, pontine and mesencephalic atrophy compared to ALS, suggesting that volume reductions are primarily caused by upper motor neuron degeneration. Furthermore, the medullar atrophy observed in PLS was not only confirmed with reference to healthy controls but also in contrast to disease controls. It is also noteworthy that using only a 4-month follow-up interval progressive volume loss can be detected in all three brainstem segments. Our morphometric analyses revealed focal density reductions in ALS compared to healthy controls in the bilateral mesencephalic crura where the descending corticospinal and corticonuclear tracts run. This further supports the notion the UMN degeneration contributes to brainstem volume reductions. This is echoed by the ALS FTD contrast which revealed focal changes in the medullar pyramids. The ALS PLS morphometric comparison is particularly interesting as both conditions are associated with widespread UMN degeneration. This contrast revealed widespread peri-aqueduct mesencephalic, central and posterior pontine grey matter changes.

Our vertex analyses also confirmed the symmetric involvement of the medullary pyramids in ALS. In contrast to PLS, ALS patients also exhibited widespread posterior pontine shape deformations including atrophy of the floor of the fourth ventricle as historically described by Clarke in 1867 ([@bib0022]). The widespread pontine shape deformations detected in ALS in contrast to PLS raises important questions about central brainstem involvement in ALS. As vertex analyses are essentially surface-projected representations of atrophy, the circumferential, anterior-posterior-lateral deformation detected in ALS compared to PLS ([Fig. 2](#fig0002){ref-type="fig"}(C)) is likely to be driven by central volume reductions i.e. grey matter degeneration. This would not only be consistent with the differential grey matter (LMN / CNN) involvement in ALS compared to PLS clinically, but also consistent with our morphometric findings, where central pontine and mesencephalic density reductions were also detected in ALS compared to PLS ([Fig. 3](#fig0003){ref-type="fig"}(C)). The integrative interpretation of the shape and morphometric alterations in ALS compared to PLS, which is a pure UMN condition, suggest that brainstem grey matter degeneration can be detected in vivo. In summary, while overall volume reductions are more prominent in PLS ([Fig. 1](#fig0001){ref-type="fig"}) vertex and voxelwise analyses capture central brainstem pathology in ALS ([Figs. 2](#fig0002){ref-type="fig"}(C) and [3](#fig0003){ref-type="fig"}(C)).Fig. 2Anatomical patterns of brainstem pathology based on vertex analyses correcting for age, gender, education and total intracranial volumes. Shape deformation in ALS are shown compared to healthy controls (A), disease controls (B) and PLS patients (C). 3D brainstem mesh is presented in blue (A), green (B) and pink (C). Patterns of atrophy is illustrated in orange with respect to healthy controls (A), in red with reference to disease controls (B) and blue in comparison to PLS patients (C). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig 2Fig. 3Morphometric changes in the brainstem **A**, Morphometric brainstem alterations in ALS patients compared to healthy controls at *p* \< .05 TFCE FWE corrected for age, gender, education and TIV. **B**, Morphometric brainstem alterations in ALS patients compared to disease controls (FTD) at *p* \< .05 TFCE FWE corrected for age, gender, education and TIV. **C**, Morphometric brainstem alterations in ALS patients compared to PLS patients at *p* \< .05 TFCE FWE corrected for age, gender, education and TIV. Statistical maps are presented in MNI space, MNI coordinates are provided under each view, and the brainstem mask is presented as a white underlay. Radiological convention is used; Lt -- Left, Rt -- Right.Fig 3

Surprisingly few human imaging studies have specifically evaluated brain stem structures in ALS, but some whole brains studies have commented on infratentorial changes. Diffusion tensor imaging studies have been inconsistent in detecting pyramidal tract degeneration at medullar or pontine levels. Some studies readily detected inferior brain stem diffusivity changes ([@bib0007]; [@bib0009]; [@bib0052]) while others only captured mesencephalic pyramidal tract alterations ([@bib0053]). Brainstem FA reductions based on pooled multisite data have been linked to stage 2 of a recently proposed pathological staging system ([@bib0054]). The findings of functional studies in ALS are even more conflicting ([@bib0055]; [@bib0092]). Several PET studies have shown increased pontine metabolism ([@bib0056]) which was interpreted as reactive astrocytosis ([@bib0057]). Hypermetabolism in the brainstem has been linked to bulbar onset ([@bib0056]) and *C9orf72* hexanucleotide repeats ([@bib0058]; [@bib0059]). Some spectroscopy studies however have detected decreased Naa/Cr ratios in the brainstem ([@bib0060]; [@bib0061]) while other did not ([@bib0062]; [@bib0063]). Animal imaging studies enable the histological interpretation of radiological changes ([@bib0064]; [@bib0065]) and high-field SOD1 transgenic mouse models showed T2 weighted hyperintensities in the nucleus ambiguus, facial nucleus, trigeminal motor nucleus, rostroventrolateral reticular nucleus, lateral paragigantocellular nucleus and the substantia nigra with associated neuronal loss of histological evaluation ([@bib0066]). Our morphometric and vertex analyses captured central pontine and inferior mesencephalic changes in ALS compared to PLS. Few imaging studies have evaluated lower motor neuron pathology to date in ALS, and without exception, these were advanced, quantitative spinal cord imaging studies, where the accurate segmentation of white and grey matter components is possible ([@bib0067],[@bib0068]).

The benefit of using standard T1-weighted sequences and morphometric analyses is that high resolution 3D T1W sequences are typically already part of clinical protocols and are readily available on any imaging platform irrespective of manufacturer or field strength. Morphometric brain stem measures could therefore be easily integrated in clinical trial protocols and data acquisition could be harmonised across multiple centres ([@bib0054]; [@bib0069]). The brainstem measures derived from T1-weighted data are therefore relatively attractive candidate biomarkers as they can be acquired non-invasively without special sequences, the acquisition time is typically short (\<10 min), the measures discriminate patients from disease controls, and the derived metrics exhibit progressive change over time.

The identification of imaging measures which readily discriminate ALS patients from healthy and disease controls is hugely relevant for emerging machine learning applications ([@bib0021]) and survival prediction ([@bib0070]). ALS is associated with strikingly focal anatomical vulnerability profiles ([@bib0071]) which enable disease-specific feature selection for classification algorithms ([@bib0072]; [@bib0073]). Classification models enable the categorisation of blinded datasets into diagnostic, phenotypic or prognostic categories and the incorporation of the discriminatory brain regions such as the brainstem is likely to increase the accuracy of such models further ([@bib0067]; [@bib0074]).

Longitudinal imaging in ALS is typically limited by high attrition rates ([@bib0001]) and relatively few large presymptomatic studies have been published to date ([@bib0003]; [@bib0075]; [@bib0076]). Despite the challenges of longitudinal imaging, a number of multi-timepoint studies have now been published ([@bib0077]; [@bib0078]) which suggest early white matter degeneration with a ceiling effect and progressive grey mater degeneration. From a biomarker point of view, the ability to track progressive changes in the later stages of the disease is essential; as indices exhibiting early ceiling effects are not suitable for monitoring.

Despite a number of pioneering studies, relatively little is known of the imaging profile of PLS and existing studies suffer from considerable sample size limitations. Furthermore, most PLS studies report overlapping imaging patterns with ALS ([@bib0079]; [@bib0080]), highlighting motor cortex ([@bib0081]; [@bib0082]), pyramidal tract ([@bib0079]; [@bib0083]), and corpus callosum pathology ([@bib0084]; [@bib0085]) and very few PLS studies highlight distinctive imaging features ([@bib0016], [@bib0028]; [@bib0086]). Our data indicate that brainstem atrophy is particularly marked in PLS and the differences between the ALS and PLS cohort are statistically significant. The description of features which discriminate PLS and ALS may have implications for the categorisation of UMN predominant patients and 'suspected PLS' patients who don\'t fulfil current diagnostic criteria ([@bib0033][@bib0087]).

The presented study has several limitations. No post-mortem data are available to validate our imaging findings which would be of particular interest in the PLS where patterns of pTDP-43 burden are poorly characterised. The longitudinal arm of the study is a two-time point design which precludes commenting on linear versus exponential longitudinal changes. While we intentionally used T1-weighted data alone in the various analysis streams, novel diffusion sequences such as HARDI, Q-ball imaging or NODDI ([@bib0088]; [@bib0089]) may have been particularly useful in characterising crossing fibre integrity in the brainstem. Notwithstanding these limitations, our study provides evidence that standard T1-weighted data can be used to detect global and focal brainstem pathology in motor neuron diseases in contrast to both healthy and disease controls.

5. Conclusions {#sec0018}
==============

Progressive brainstem pathology can be detected in ALS in vivo and brainstem measures may have a biomarker role in diagnostic, monitoring and prognostic applications.
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